Fol. Biol. 2014, 60, 261-267

https://doi.org/10.14712/fb2014060060261

Protein and mRNA Levels of YKL-40 in High-Grade Glioma

M. H. Kazakova1, D. N. Staneva2, I. G. Koev3, D. G. Staikov4, N. Mateva5, P. T. Timonov4, G. A. Miloshev2, Victoria S. Sarafian1

1Department of Medical Biology, Medical Faculty, Faculty od Public Health Medical University-Plovdiv, Plovdiv, Bulgaria
2Laboratory of Yeast Molecular Genetics, Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Sofia, Bulgaria
3Department of Neurosurgery, Medical Faculty, Faculty od Public Health Medical University-Plovdiv, Plovdiv, Bulgaria
4Department of General and Clinical Pathology and Forensic Medicine, Medical Faculty, Faculty od Public Health Medical University-Plovdiv, Plovdiv, Bulgaria
5Department of Medical Informatics, Biostatistics and e-Learning, Medical Faculty, Faculty od Public Health Medical University-Plovdiv, Plovdiv, Bulgaria

Received July 2014
Accepted September 2014

References

1. Antonelli, M., Massimino, M., Morra, I., Garre, M. L., Gardiman, M. P., Buttarelli, F. R., Arcella, A., Giangaspero, F. (2012) Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL-40 and prognostic significance. Neuropathology 32, 133-138. <https://doi.org/10.1111/j.1440-1789.2011.01252.x>
2. Bernardi, D., Padoan, A., Ballin, A., Sartori, M. T., Manara, R., Scienza, R., Plebani, M., Puppa, A. D . (2012) Serum YKL-40 following resection for cerebral glioblastoma. J. Neurooncol. 107, 99-305. <https://doi.org/10.1007/s11060-011-0762-7>
3. Central Brain Tumor Registry of the United States, http://www.CBTRUS.org
4. Faibish, M., Francescone, R., Bentley, B., Yan, W., Shao, R. (2011) A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol. Cancer. Ther. 10, 742-751. <https://doi.org/10.1158/1535-7163.MCT-10-0868>
5. Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., Yan, W., Bentley, B., Shao, R. (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286, 15332-15343. <https://doi.org/10.1074/jbc.M110.212514>
6. Fusetti, F., Pijning, T., Kalk, K. H., Bos, E., Dijkstra, B. W. (2003) Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J. Biol. Chem. 278, 37753-37760. <https://doi.org/10.1074/jbc.M303137200>
7. Horbinski, C., Wang, G., Wiley, C. (2010) YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int. J. Clin. Exp. Pathol. 3, 226-237.
8. Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., Holland, E. C. (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. 12, 5698-5704. <https://doi.org/10.1158/1078-0432.CCR-06-0181>
9. Huber, R. M., Rajski, M., Sivasankaran, B., Moncayo, G., Hemmings, B. A., Merlo, A. (2013) D eltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. PLoS One 8, e57793. <https://doi.org/10.1371/journal.pone.0057793>
10. Johansen, J. S. (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 53, 172-209.
11. Junker, N., Johansen, J. S., Andersen, C. B., Kristjansen, P. E. (2005) Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48, 223-231. <https://doi.org/10.1016/j.lungcan.2004.11.011>
12. Kazakova, M., Batalov, A., Deneva, T., Mateva, N., Kolarov, Z., Sarafian, V. (2013) Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol. Int. 33, 341-346. <https://doi.org/10.1007/s00296-012-2387-3>
13. Lal, A., Lash, A. E., Altschul, S. F., Velculescu, V., Zhang, L., McLendon, R. E., Marra, M. A., Prange, C., Morin, P. J., Polyak, K., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., Strausberg, R. L., Riggins, G. J. (1999) A public database for gene expression in human cancers. Cancer Res. 59, 5403-5407.
14. Markert, J. M., Fuller, C. M., Gillespie, G. Y., Bubien, J. K., McLean, L. A., Hong, R. L., Lee, K., Gullans, S. R., Mapstone, T. B., Benos, D . J. (2001) D ifferential gene expression profiling in human brain tumors. Physiol. Genomics 5, 21-33. <https://doi.org/10.1152/physiolgenomics.2001.5.1.21>
15. Nutt, C., Betensky, R., Brower, M., Batchelor, T. T., Louis, D. N., Stemmer-Rachmaninov, A. O. (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of highgrade gliomas. Clin. Cancer Res. 11, 2258-2264. <https://doi.org/10.1158/1078-0432.CCR-04-1601>
16. Pan, J. J., Ge, Y. S., Xu, G. L., Jia, W. D., Liu, W. F., Li, J. S., Liu, W. B. (2013) The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 139, 1043-1054. <https://doi.org/10.1007/s00432-013-1415-3>
17. Pelloski, C. E, Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., Passe, S., Jenkins, R. B., Aldape, K. D . (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 11, 3326-3334. <https://doi.org/10.1158/1078-0432.CCR-04-1765>
18. Renkema, G. H., Boot, R.G., Au, F. L., Donker-Koopman, W. E., Strijland, A., Muijsers, A. O., Hrebicek, M., Aerts, J. M. (1998) Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem. 251, 504-509. <https://doi.org/10.1046/j.1432-1327.1998.2510504.x>
19. Roslind, A., Johansen, J. S. (2009) YKL-40: A novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol. Biol. 511, 159-184. <https://doi.org/10.1007/978-1-59745-447-6_7>
20. Schultz, N. A., Johansen, J. S. (2010) YKL-40 – a protein in the field of translational medicine: a role as a biomarker in cancer patients? Cancers (Basel) 2, 1453-1491. <https://doi.org/10.3390/cancers2031453>
21. Schwartzbaum, J., Fisher, J. L., Aldape, K. D., Wrensch, M. (2006) Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2, 494-503. <https://doi.org/10.1038/ncpneuro0289>
22. Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., Yan, W. (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456–4468. <https://doi.org/10.1038/onc.2009.292>
23. Shao, R. (2013) YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front. Physiol. 4, 122. <https://doi.org/10.3389/fphys.2013.00122>
24. Shostak, K., Labunskyy, V., Dmitrenko, V., Malisheva, T., Shamayev, M., Rozumenko, V., Zozulya, Y., Zehetner, G., Kavsan, V. (2003) HC gp-39 gene is upregulated in glioblastomas. Cancer Lett. 198, 203-210. <https://doi.org/10.1016/S0304-3835(03)00310-0>
25. Stawerski, P., Wagrowska-Danilewicz, M., Stasikowska-Kanicka, O., D anilewicz, M. (2011) Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol. Res. Pract. 207, 573-576. <https://doi.org/10.1016/j.prp.2011.06.008>
26. Tanwar, M. K., Gilbert, M. R., Holland, E. C. (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62, 4364-4368.
27. Yamac, D., Ozturk, B., Coskun, U., Tekin, E., Sancak, B., Yildiz, R., Atalay, C. (2008) Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv. Ther. 25, 801-809. <https://doi.org/10.1007/s12325-008-0082-2>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive